NASDAQ:IMV

IMV Stock Forecast, Price & News

$2.82

-0.08 (-2.76 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.78

Now: $2.82▼

$2.88

50-Day Range

$2.86

MA: $3.29▼

$3.99

52-Week Range

$1.50

Now: $2.82▼

$6.82

Volume116,009 shs

Average Volume277,310 shs

Market Capitalization$190.71 million

P/E RatioN/A

Dividend YieldN/A

Beta1.69

IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IMV

Previous Symbol

CUSIPN/A

CIKN/A

Webimv-inc.com

Phone902 492 1819

Employees62

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.20

Current Ratio7.03

Quick Ratio7.03

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$430,000.00

Price / Sales443.51

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.10 per share

Price / Book28.20

Profitability

EPS (Most Recent Fiscal Year)($0.41)

Net Income$-20,620,000.00

Net Margins-9,661.54%

Return on Equity-180.04%

Return on Assets-91.98%

Miscellaneous

Outstanding Shares67,628,000

Market Cap$190.71 million

Next Earnings Date5/21/2021 (Estimated)

OptionableOptionable

Headlines

Is IMV (TSE:IMV) A Risky Investment? - Yahoo Finance
April 8, 2021 | finance.yahoo.com

Is IMV (TSE:IMV) A Risky Investment?
April 8, 2021 | finance.yahoo.com

IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA - Business Wire
April 8, 2021 | businesswire.com

IMV to advance its lead asset with Keytruda in mid-stage blood cancer study - Seeking Alpha
April 8, 2021 | seekingalpha.com

IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients
April 7, 2021 | finance.yahoo.com

IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA
April 7, 2021 | finance.yahoo.com

IMV Inc. (NASDAQ:IMV) Receives Average Recommendation of "Hold" from Analysts
April 5, 2021 | americanbankingnews.com

IMV Inc. (NASDAQ:IMV) Short Interest Update
April 2, 2021 | americanbankingnews.com

-$0.12 EPS Expected for IMV Inc. (NASDAQ:IMV) This Quarter
April 2, 2021 | americanbankingnews.com

CytoDyn files new protocol with FDA for four doses of leronlimab for critically ill coronavirus patients - Proactive Investors USA
April 1, 2021 | proactiveinvestors.com

CytoDyn"s leronlimab decreases mortality by 82% among critically ill coronavirus patients after two weeks in CD12 trial - Proactive Investors USA
March 30, 2021 | proactiveinvestors.com

CytoDyn Says Its Covid-19 Drug Candidate Reduced Mortality Rate By 82% At 14 Days- Quick Facts - Nasdaq
March 30, 2021 | nasdaq.com

CytoDyn's Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients - StreetInsider.com
March 30, 2021 | streetinsider.com

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19 - StreetInsider.com
March 29, 2021 | streetinsider.com

IMV (NASDAQ:IMV) Rating Reiterated by Leede Jones Gab
March 23, 2021 | americanbankingnews.com

IMV Inc. (NASDAQ:IMV) Forecasted to Earn FY2021 Earnings of ($0.38) Per Share
March 22, 2021 | americanbankingnews.com

IMV Inc. to Post Q1 2021 Earnings of ($0.14) Per Share, Raymond James Forecasts (NASDAQ:IMV)
March 22, 2021 | americanbankingnews.com

Stocks Stumble at Outset - Baystreet.ca
March 18, 2021 | baystreet.ca

IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results - Business Wire
March 18, 2021 | businesswire.com

IMV Inc. (IMV) Q4 2020 Earnings Call Transcript
March 17, 2021 | fool.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.78 out of 5 stars

Medical Sector

1201st out of 2,016 stocks

Pharmaceutical Preparations Industry

534th out of 771 stocks

3.3 Analyst's Opinion

Consensus Rating
IMV has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.54, IMV has a forecasted upside of 202.9% from its current price of $2.82.
Amount of Analyst Coverage
IMV has only been the subject of 3 research reports in the past 90 days.

0.6 Community Rank

Outperform Votes
IMV has received 1 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IMV has received 8 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IMV has received 88.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote “Outperform” if you believe IMV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IMV does not currently pay a dividend.
Dividend Growth
IMV does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IMV insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 20.74% of the stock of IMV is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for IMV are expected to decrease in the coming year, from ($0.36) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IMV is -6.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IMV is -6.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IMV has a P/B Ratio of 28.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$2.82

-0.08 (-2.76 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV (NASDAQ:IMV) Frequently Asked Questions

Is IMV a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMV stock.
View analyst ratings for IMV or view top-rated stocks.

What stocks does MarketBeat like better than IMV?

Wall Street analysts have given IMV a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IMV wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IMV?

IMV saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 839,200 shares, an increase of 31.9% from the February 28th total of 636,400 shares. Based on an average trading volume of 324,100 shares, the short-interest ratio is currently 2.6 days. Currently, 1.4% of the shares of the company are sold short.
View IMV's Short Interest.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for IMV.

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) released its earnings results on Tuesday, March, 16th. The company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.01. IMV had a negative net margin of 9,661.54% and a negative trailing twelve-month return on equity of 180.04%.
View IMV's earnings history.

How has IMV's stock price been impacted by Coronavirus?

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMV shares have increased by 18.5% and is now trading at $2.82.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for IMV?

7 Wall Street analysts have issued 12-month target prices for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's stock price to reach $8.54 in the next year. This suggests a possible upside of 202.9% from the stock's current price.
View analysts' price targets for IMV or view top-rated stocks among Wall Street analysts.

Who are IMV's key executives?

IMV's management team includes the following people:

Mr. Frederic Ors M.B.A., B.Sc., M.A., CEO & Director (Age 47)
Ms. Joanne Schindler, Chief Medical Officer
Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations
Ms. Annie Tanguay B.Sc., Sr. VP of Quality & Compliance
Delphine Davan, Director of Communications
Mr. Andrew Hall M.Sc., Chief Bus. Officer
Dr. Marianne Stanford, VP of R&D

Who are some of IMV's key competitors?

Some companies that are related to IMV include Karyopharm Therapeutics (KPTI), Lexicon Pharmaceuticals (LXRX), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), ORIC Pharmaceuticals (ORIC), BELLUS Health (BLUSF), Veru (VERU), ZIOPHARM Oncology (ZIOP), Chimerix (CMRX), VBI Vaccines (VBIV), Ardelyx (ARDX), Calliditas Therapeutics AB (publ) (CALT), Emisphere Technologies (EMIS), Clovis Oncology (CLVS) and OrganiGram (OGI).
View all of IMV's competitors.

What is IMV's stock symbol?

IMV trades on the NASDAQ under the ticker symbol "IMV."

How do I buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $2.82.

How much money does IMV make?

IMV has a market capitalization of $190.71 million and generates $430,000.00 in revenue each year. The company earns $-20,620,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does IMV have?

IMV employs 62 workers across the globe.

What is IMV's official website?

The official website for IMV is imv-inc.com.

Where are IMV's headquarters?

IMV is headquartered at 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4.

How can I contact IMV?

IMV's mailing address is 130 EILEEN STUBBS AVENUE SUITE 19, DARTMOUTH A5, B3B 2C4. The company can be reached via phone at 902 492 1819 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here